[Other] Cost effectiveness analysis of additional NK-1 receptor antagonist to olanzapine, ondansetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin.

Closed

LNDS Post time 2024-5-7 21:46:57 | Show all posts |Read mode

Reward20points

journal：Journal of Clinical Oncology

Authors：Wasamol Mahaparn; Chalermchai Lertanansit; Chanida Vinayanuwattikun; Suebpong Tanasanvimon

Published date：2020-5-20

DOI：10.1200/jco.2020.38.15_suppl.e19398

Article link：http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19398

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

LNDS Lv.2

Junior Member

post
reply
points
120

[Other] Cost effectiveness analysis of additional NK-1 receptor antagonist to olanzapine, ondansetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin. Copy

Reply

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Other] Cost effectiveness analysis of additional NK-1 receptor antagonist to olanzapine, ondansetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin.